menu
    • menu

    Find Ibrutinib manufacturers, exporters & distributors on PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs Ibrutinib

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    49

    API Suppliers

    API Suppliers

    17

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    4

    EU WC

    EU WC

    0

    KDMF

    KDMF

    16

    NDC API

    NDC API

    0

    VMF

    NDC API

    39

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 6,734

    MARKET PLACE

    3

    API

    5

    FDF

    38INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    65

    FDF Dossiers

    FDF Dossiers

    31

    FDA Orange Book

    FDA (Orange Book)

    14

    Europe

    Europe

    2

    Canada

    Canada

    7

    Australia

    Australia

    5

    South Africa

    South Africa

    6

    Listed Dossiers

    Listed Dossiers

    63DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    14

    Others

    PATENTS & EXCLUSIVITIES

    732

    US Patents

    41

    US Exclusivities

    1

    Health Canada Patents

    DIGITAL CONTENT

    8

    Data Compilation #PharmaFlow

    1

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    244

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    2,147,483,647

    Annual Reports

    56,470

    Finished Drug Prices

    Listed Dossiers

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 936563-96-1, Pci-32765, Imbruvica, Pci 32765, Ibrutinib (pci-32765), Pci-32765 (ibrutinib)
    Molecular Formula
    C25H24N6O2
    Molecular Weight
    440.5  g/mol
    InChI Key
    XYFPWWZEPKGCCK-GOSISDBHSA-N
    FDA UNII
    1X70OSD4VX
    Ibrutinib
    Ibrutinib is an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.
    Ibrutinib is a Kinase Inhibitor. The mechanism of action of ibrutinib is as a Protein Kinase Inhibitor.
    1 2D Structure

    Ibrutinib

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
    2.1.2 InChI
    InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1
    2.1.3 InChI Key
    XYFPWWZEPKGCCK-GOSISDBHSA-N
    2.1.4 Canonical SMILES
    C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
    2.1.5 Isomeric SMILES
    C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N
    2.2 Other Identifiers
    2.2.1 UNII
    1X70OSD4VX
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-((3r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1- Yl)prop-2-en-1-one

    2. Imbruvica

    3. Pci 32765

    4. Pci-32765

    5. Pci32765

    2.3.2 Depositor-Supplied Synonyms

    1. 936563-96-1

    2. Pci-32765

    3. Imbruvica

    4. Pci 32765

    5. Ibrutinib (pci-32765)

    6. Pci-32765 (ibrutinib)

    7. Cra-032765

    8. Pc-32765

    9. (r)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one

    10. 1x70osd4vx

    11. Pci-32765-00

    12. Chebi:76612

    13. Pci32765

    14. 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one

    15. 1-((3r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1- Yl)prop-2-en-1-one

    16. 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one

    17. 1-{(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one

    18. 2-propen-1-one, 1-((3r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-

    19. (r)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one

    20. (r)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.

    21. Ibrutinib [usan]

    22. Ibrutinib [usan:inn]

    23. Unii-1x70osd4vx

    24. Ibrutinibum

    25. Jnj 02

    26. Imbruvica (tn)

    27. Ibrutinib- Bio-x

    28. Cra 032765

    29. Ibrutinib [inn]

    30. Ibrutinib [jan]

    31. Ibrutinib [mi]

    32. Ibrutinib (jan/usan)

    33. Ibrutinib [vandf]

    34. Ibrutinib [who-dd]

    35. Imbruvica; Pci-32765

    36. 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one

    37. Mls006010041

    38. Schembl201859

    39. Gtpl6912

    40. Ibrutinib [orange Book]

    41. Chembl1873475

    42. Hsdb 8260

    43. Dtxsid60893450

    44. Ex-a066

    45. Amy27873

    46. Bdbm50357312

    47. Mfcd20261150

    48. Nsc800769

    49. Zinc35328014

    50. Akos022185476

    51. Db09053

    52. Ex-5960

    53. Nsc-800769

    54. Ncgc00187912-01

    55. Ncgc00187912-02

    56. Ncgc00187912-03

    57. Ncgc00187912-12

    58. Ac-26942

    59. Bi164531

    60. Hy-10997

    61. Smr004701213

    62. Sw218096-2

    63. D10223

    64. A1-01649

    65. J-523872

    66. Q5984881

    67. (r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-ylprop-2-en-1-one

    68. 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one

    69. 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]

    70. 1-[(3r)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one

    71. Ibrutinibci-32765mbruvica(r)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one

    72. Piperidin-1-yl]prop-2-en-1-one1-{3-[4-amino-3-(4-phenoxy-phenyl)-pyrazolo[3,4-d]pyrimidin-1-yl]-piperidin-1-yl}-propenone

    2.4 Create Date
    2008-06-30
    3 Chemical and Physical Properties
    Molecular Weight 440.5 g/mol
    Molecular Formula C25H24N6O2
    XLogP33.6
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count5
    Exact Mass440.19607403 g/mol
    Monoisotopic Mass440.19607403 g/mol
    Topological Polar Surface Area99.2 Ų
    Heavy Atom Count33
    Formal Charge0
    Complexity678
    Isotope Atom Count0
    Defined Atom Stereocenter Count1
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Therapeutic Uses

    Ibrutinib is a novel oral tyrosine kinase inhibitor that irreversibly binds and inhibits tyrosine-protein kinase BTK (Bruton tyrosine kinase). BTK has been found to be important in the function of B-cell receptor signaling and therefore in the maintenance and expansion of various B-cell malignancies including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Targeting BTK with ibrutinib has been found to be an effective strategy in treating these malignancies. Phase I clinical testing in non-Hodgkin's lymphomas and CLL showed that the drug was extremely well tolerated with no major dose-limiting toxicities and a 54% overall response rate. Subsequently, two phase Ib/II studies were performed on patients with CLL, one in relapsed/refractory CLL and one in previously untreated elderly patients with CLL. Both of these studies continued to show good tolerability of the drug and an overall response rate of about 71% with extended duration of response. Another phase II study using ibrutinib in relapsed/refractory MCL was conducted and also showed that it was well tolerated with an overall response rate of 68% and extended duration of response. Due to these results, the U.S. Food and Drug Administration granted accelerated approval for ibrutinib in November 2013 for patients with MCL who had received at least one prior therapy and in February 2014 for patients with CLL who had received at least one prior therapy. This review will discuss the preclinical pharmacology, pharmacokinetics and clinical efficacy to date of ibrutinib in the treatment of CLL and MCL.

    PMID:24918646 McDermott J, Jimeno A; Drugs Today (Barc) 50(4):291-300 (2014)

    /CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health(NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Ibrutinib is included in the database.

    NIH/NLM; ClinicalTrials.Gov. Available from, as of July 18, 2015: https://clinicaltrials.gov/search/intervention=%22PCI-32765%22+OR+%22CRA-032765%22+OR+Ibrutinib+OR+%22PCI+32765%22+OR+PCI32765

    Imbruvica is indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials. /Included in US product label/

    NIH; DailyMed. Current Medication Information for Imbruvica (Ibrutinib) Capsule (Updated: February 2015). Available from, as of May 4, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44

    Imbruvica is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. /Included in US product label/

    NIH; DailyMed. Current Medication Information for Imbruvica (Ibrutinib) Capsule (Updated: February 2015). Available from, as of May 4, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44

    For more Therapeutic Uses (Complete) data for IBRUTINIB (7 total), please visit the HSDB record page.

    4.2 Drug Warning

    Fatal and non-fatal infections have occurred with IMBRUVICA therapy. Grade 3 or greater infections occurred in 14% to 26% of patients. Cases of progressive multifocal leukoencephalopathy (PML) have occurred in patients treated with IMBRUVICA. Monitor patients for fever and infections and evaluate promptly.

    NIH; DailyMed. Current Medication Information for Imbruvica (Ibrutinib) Capsule (Updated: February 2015). Available from, as of July 22, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44#S1.4

    Fatal bleeding events have occurred in patients treated with IMBRUVICA. Grade 3 or higher bleeding events (subdural hematoma, gastrointestinal bleeding, hematuria and post procedural hemorrhage) have occurred in up to 6% of patients. Bleeding events of any grade, including bruising and petechiae, occurred in approximately half of patients treated with IMBRUVICA. The mechanism for the bleeding events is not well understood. IMBRUVICA may increase the risk of hemorrhage in patients receiving antiplatelet or anticoagulant therapies. Consider the benefit-risk of withholding IMBRUVICA for at least 3 to 7 days pre and post-surgery depending upon the type of surgery and the risk of bleeding.

    NIH; DailyMed. Current Medication Information for Imbruvica (Ibrutinib) Capsule (Updated: February 2015). Available from, as of July 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44#S1.4

    Treatment-emergent Grade 3 or 4 cytopenias including neutropenia (range, 19 to 29%), thrombocytopenia (range, 5 to 17%), and anemia (range, 0 to 9%) occurred in patients treated with IMBRUVICA. Monitor complete blood counts monthly.

    NIH; DailyMed. Current Medication Information for Imbruvica (Ibrutinib) Capsule (Updated: February 2015). Available from, as of July 22, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44#S1.4

    Atrial fibrillation and atrial flutter (range, 6 to 9%) have occurred in patients treated with IMBRUVICA, particularly in patients with cardiac risk factors, acute infections, and a previous history of atrial fibrillation. Periodically monitor patients clinically for atrial fibrillation. Patients who develop arrhythmic symptoms (e.g., palpitations, lightheadedness) or new onset dyspnea should have an ECG performed. If atrial fibrillation persists, consider the risks and benefits of IMBRUVICA treatment and dose modification.

    NIH; DailyMed. Current Medication Information for Imbruvica (Ibrutinib) Capsule (Updated: February 2015). Available from, as of July 22, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44#S1.4

    For more Drug Warnings (Complete) data for IBRUTINIB (8 total), please visit the HSDB record page.

    4.3 Drug Indication

    Ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapy. Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that develops in the outer edge of a lymph node. MCL is usually diagnosed at late stages and it is easily spread into bone marrow, spleen, liver and gastrointestinal tract. Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who have at least one prior therapy. CLL is a type of cancer caused by an overproduction of lymphocytes by the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness. Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion. CLL with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the TP53 gene. The remaining allele is mainly inactivated and thus, this type of leukemia is unresponsive to p53-dependent treatments. Ibrutinib is indicated for the treatment of patients with Waldenstrom's Macroglobulinemia (WM). WM, also called lymphoplasmacytic lymphoma, is a type of non-Hodgkin lymphoma in which the cancer cells make large amounts of macroglobulin. The macroglobulin is a monoclonal protein that corresponds to the type of IgM antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous system.

    FDA Label

    IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

    IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5. 1).

    IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.

    IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenstrms macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.

    Treatment of chronic Graft versus Host Disease (cGvHD)

    Treatment of lymphoplasmacytic lymphoma

    Treatment of mantle cell lymphoma

    Treatment of lymphoplasmacytic lymphoma

    Treatment of mantle cell lymphoma

    Treatment of mature B-cell neoplasms

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    In vitro studies have shown an induction of CLL cell apoptosis even in presence of prosurvival factors. It has also been reported an inhibition of CLL cell survival and proliferation as well as an impaired in cell migration and a reduction in the secretion of chemokines such as CCL3 and CCL4. The latter effect has been shown to produce regression in xenograft mouse models. Clinical studies for relapsed/refractory CLL in phase I and II showed an approximate 71% of overall response rate.. In the case of relapsed/refractory mantle cell lymphoma, approximately 70% of the tested patients presented a partial or complete response.. In clinical trials for relapsed/refractory diffuse large B-cell lymphoma, a partial response was found in between 15-20% of the patients studied; while for patients with relapsed/refractory Waldenstrom's macroglobulinemia, a partial response was observed in over 75% of the patients tested. Finally, for patients with relapsed/refractory follicular lymphoma, a partial to complete response was obtained in approximately 54% of the patients.

    5.2 FDA Pharmacological Classification
    5.2.1 Active Moiety
    IBRUTINIB
    5.2.2 FDA UNII
    1X70OSD4VX
    5.2.3 Pharmacological Classes
    Protein Kinase Inhibitors [MoA]; Kinase Inhibitor [EPC]
    5.3 ATC Code

    L01EL01

    L01XE27

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    L - Antineoplastic and immunomodulating agents

    L01 - Antineoplastic agents

    L01E - Protein kinase inhibitors

    L01EL - Bruton's tyrosine kinase (btk) inhibitors

    L01EL01 - Ibrutinib

    5.4 Absorption, Distribution and Excretion

    Absorption

    Ibrutinib is rapidly absorbed after oral administration and it presents a Cmax, tmax and AUC of approximately 35 ng/ml, 1-2 hour and 953 mg.h/ml respectively.

    Route of Elimination

    The cumulative excretion of ibrutinib in urine is of about 7.8% of the administered dose and most of this excretion is found during the first 24 hours after administration. In feces, the cumulative excretion accounts for 80% of the administered dose and the excretion occurs within 48 hours of the initial administration. The total excretion of ibrutinib during the first 168 hours after initial administration accounts for 88.5% of the administered dose.

    Volume of Distribution

    The volume of distribution at steady-state of ibrutinib is in approximately 10,000 L.

    Clearance

    In patients with normal renal function, the clearance rate is in the range of 112-159 ml/min.

    5.5 Metabolism/Metabolites

    Three metabolic pathways have been identified according to the possible metabolites. These pathways are the hydroxylation of the phenyl group (M35), the opening of the piperidine with a reduction of the primary alcohol (M34) and the oxidation to a carboxylic acid and epoxidation of the ethylene followed by a hydrolysis to the formation of dihydrodiol (PCI-45227). The latter metabolite presents also 15 times lower inhibitory activity against BTK. The metabolism of ibrutinib is mainly performed by CYP3A5 and CYP3A4. and in a minor extent it is seen to be performed by CYP2D6.

    Since 2014, Ibrutinib has been available as a new drug for the treatment of leukemic diseases. Ibrutinib (Imbruvica) is metabolized in the liver mainly by the isoenzyme CYP3A4 and to a minor extent by CYP2D6. Simultaneous application of Imbruvica and consumption of foods containing secondary metabolites strongly inhibiting the CYP3A4 isoform, could significantly influence the toxicity of this drug. This article references the respective foods.

    PMID:25975016 Kronabel D; Clin Lab 61 (3-4): 443-4 (2015)

    5.6 Biological Half-Life

    The elimination half-life of ibrutinib is of approximately 4-6 hours.

    5.7 Mechanism of Action

    Ibrutinib is an inhibitor of Brutons tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the active site of BTK (Cys481), leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-.

    Ibrutinib is a novel oral tyrosine kinase inhibitor that irreversibly binds and inhibits tyrosine-protein kinase BTK (Bruton tyrosine kinase). BTK has been found to be important in the function of B-cell receptor signaling and therefore in the maintenance and expansion of various B-cell malignancies including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Targeting BTK with ibrutinib has been found to be an effective strategy in treating these malignancies. Phase I clinical testing in non-Hodgkin's lymphomas and CLL showed that the drug was extremely well tolerated with no major dose-limiting toxicities and a 54% overall response rate. Subsequently, two phase Ib/II studies were performed on patients with CLL, one in relapsed/refractory CLL and one in previously untreated elderly patients with CLL. Both of these studies continued to show good tolerability of the drug and an overall response rate of about 71% with extended duration of response. Another phase II study using ibrutinib in relapsed/refractory MCL was conducted and also showed that it was well tolerated with an overall response rate of 68% and extended duration of response. Due to these results, the U.S. Food and Drug Administration granted accelerated approval for ibrutinib in November 2013 for patients with MCL who had received at least one prior therapy and in February 2014 for patients with CLL who had received at least one prior therapy. This review will discuss the preclinical pharmacology, pharmacokinetics and clinical efficacy to date of ibrutinib in the treatment of CLL and MCL.

    PMID:24918646 McDermott J, Jimeno A; Drugs Today (Barc) 50(4):291-300 (2014)

    ... In this study we report for the first time that ibrutinib is cytotoxic to malignant plasma cells from patients with multiple myeloma (MM) and furthermore that treatment with ibrutinib significantly augments the cytotoxic activity of bortezomib and lenalidomide chemotherapies. We describe that the cytotoxicity of ibrutinib in MM is mediated via an inhibitory effect on the nuclear factor-(k)B (NF-(k)B) pathway. Specifically, ibrutinib blocks the phosphorylation of serine-536 of the p65 subunit of NF-(k)B, preventing its nuclear translocation, resulting in down-regulation of anti-apoptotic proteins Bcl-xL, FLIP(L) and survivin and culminating in caspase-mediated apoptosis within the malignant plasma cells....

    PMID:22975686 Rushworth SA et al; Cell Signal 25 (1): 106-12 (2013)

    Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy that characteristically shows overexpression of cyclin-D1 due to an alteration in the t(11;14)(q13;q32) chromosomal region. Although there are some promising treatment modalities, great majority of patients with this disease remain incurable. The B-cell antigen receptor (BCR) signaling plays a crucial role in B-cell biology and lymphomagenesis. Bruton tyrosine kinase (BTK) has been identified as a key component of the BCR signaling pathway. Evidence suggests that the blockade of BTK activity by potent pharmacologic inhibitors attenuates BCR signaling and induces cell death. Notably, the expression levels and the role of BTK in MCL survival are still elusive. Here, we demonstrated a moderate to strong BTK expression in all MCL cases (n=19) compared to benign lymphoid tissues. Treatment of MCL cell lines (Mino or Jeko-1) with a potent BTK pharmacologic inhibitor, Ibrutinib, decreased phospho-BTK-Tyr(223) expression. Consistent with this observation, Ibrutinib inhibited the viability of both Mino and JeKo-1 cells in concentration- and time-dependent manners. Ibrutinib also induced a concentration-dependent apoptosis in both cell lines. Consistently, Ibrutinib treatment decreased the levels of anti-apoptotic Bcl-2, Bcl-xL, and Mcl-1 protein. These findings suggest that BTK signaling plays a critical role in MCL cell survival, and the targeting of BTK could represent a promising therapeutic modality for aggressive lymphoma.

    PMID:23962569 Cinar M et al; Leuk Res 37 (10): 1271-7 (2013)

    Ibrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK's role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival in vivo as well as cell migration and substrate adhesion in vitro.

    NIH; DailyMed. Current Medication Information for Imbruvica (Ibrutinib) Capsule (Updated: February 2015). Available from, as of May 20, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dfd0279-ff17-4ea9-89be-9803c71bab44

    API SUPPLIERS

    read-more
    read-more

    01

    Aarti Pharmalabs

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India 2024
    Booth #2.F08
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 15308-2402

    Start Marketing Date : 2024-01-31

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (200kg/200kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    Aarti Industries Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Minakem

    France

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    euroPLX 86 Munich
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMinakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Minakem Comapny Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Minakem (formerly Delmar Chemicals...

    Canada

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMinakem is manufacturing small molecules APIs including corticosteroids

    Contact Supplier Contact Supplier
    Flag Canada
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Minakem Delmar

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    LGM Pharma

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BioFlorida Conference
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Suanfarma

    Spain

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India 2024
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSuanfarma, at the Core of a Better Life.

    Contact Supplier Contact Supplier
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Suanfarma

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Faran Shimi Pharmaceutical

    Iran

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothFaran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Faran Shimi Pharmaceutical

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Supriya Lifescience

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI India 2024
    Booth #1.B20
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSupriya Lifesciences is a cGMP-compliant API manufacturing organization with a leadership position across key & niche products.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Supriya

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Tofigh Daru

    Iran

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Pharmtech & Ingredients
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.

    Contact Supplier Contact Supplier
    Flag Iran
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Tofigh Daru

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Esteve Huayi Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Esteve Huayi Pharmaceutical

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2017-05-23

    Pay. Date : 2017-05-08

    DMF Number : 31679

    Submission : 2017-05-05

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Teva API

    Israel

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    Compamed
    Not Confirmed
    arrow

    Teva API

    Israel

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Compamed
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2017-07-05

    Pay. Date : 2017-04-17

    DMF Number : 31631

    Submission : 2017-06-08

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"IBRUTINIB","year":"2021","qtr":"Q1","strtotime":1615833000,"product":"IBRUTINIB","address":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD","city":"VADODARA","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"TUNIS","customer":"TO THE ORDER OF","customerCountry":"TUNISIA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"29908.9","totalValueFC":"29600.2","currency":"USD","unitRateINR":2154936.0699999998,"date":"16-Mar-2021","totalValueINR":"2154936.07","totalValueInUsd":"29600.2","indian_port":"AHMEDABAD AIR","hs_no":"29335990","bill_no":"9397084","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TUNISIA","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC PHARMACEUTICALS LTD\\r\\nALEMBIC ROAD, VADODARA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q2","strtotime":1624645800,"product":"IBRUTINIB AMORPHOUS(QTY:20 GMS)","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"CHICAGO IL","customer":"OAKWOOD LABS","customerCountry":"UNITED STATES","quantity":"0.02","actualQuantity":"20","unit":"GMS","unitRateFc":"25.3","totalValueFC":"495.3","currency":"USD","unitRateINR":1821.25,"date":"26-Jun-2021","totalValueINR":"36425","totalValueInUsd":"495.3","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"2705167","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1628706600,"product":"IBRUTINIB (TAX INVOICE NO:1905215167 DT 10-08-2021)","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"TOKYO","customer":"CBC GROUP","customerCountry":"JAPAN","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"24504.2","totalValueFC":"2380.5","currency":"USD","unitRateINR":1765530,"date":"12-Aug-2021","totalValueINR":"176553","totalValueInUsd":"2380.5","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"3801705","productDescription":"API","marketType":"REGULATED MARKET","country":"JAPAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1636396200,"product":"IBRUTINIB FORM A","address":"","city":"","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"TEHRAN","customer":"NANO FANAVARAN DARUEI ","customerCountry":"IRAN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"401200","totalValueFC":"26936.6","currency":"INR","unitRateINR":401200,"date":"09-Nov-2021","totalValueINR":"2006000","totalValueInUsd":"26936.6","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"5878748","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1639679400,"product":"IBRUTINIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"TO THE ORDER OF","customerCountry":"TAIWAN","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"12000","totalValueFC":"2996.3","currency":"USD","unitRateINR":904000,"date":"17-Dec-2021","totalValueINR":"226000","totalValueInUsd":"2996.3","indian_port":"AHMEDABAD AIR","hs_no":"29335990","bill_no":"6823888","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1640889000,"product":"IBRUTINIB (TAX INVOICE NO:1905215305 DT","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"PRAGUE - RUZYNE","customer":"ZENTIVA","customerCountry":"CZECH REPUBLIC","quantity":"9.50","actualQuantity":"9.5","unit":"KGS","unitRateFc":"12000","totalValueFC":"113674.1","currency":"USD","unitRateINR":902526.31578947371,"date":"31-Dec-2021","totalValueINR":"8574000","totalValueInUsd":"113674.1","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"7173087","productDescription":"API","marketType":"REGULATED MARKET","country":"CZECH REPUBLIC","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1645036200,"product":"IBRUTINIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"TO THE ORDER OF","customerCountry":"TAIWAN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"13200","totalValueFC":"11273.1","currency":"USD","unitRateINR":845000,"date":"17-Feb-2022","totalValueINR":"845000","totalValueInUsd":"11273.1","indian_port":"AHMEDABAD AIR","hs_no":"29335990","bill_no":"8299340","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1648060200,"product":"IBRUTINIB","address":"12 6 214 A1, YERMARUS CAMP CROSS,H YDERABAD ROAD","city":"RAICHUR,KARNATAKA","supplier":"SHILPA MEDICARE","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"ACTAVIS INC","customerCountry":"TAIWAN","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"12000","totalValueFC":"2925.8","currency":"USD","unitRateINR":892000,"date":"24-Mar-2022","totalValueINR":"223000","totalValueInUsd":"2925.8","indian_port":"HYDERABAD AIR","hs_no":"29420090","bill_no":"9176914","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"12 6 214 A1, YERMARUS CAMP CROSS,H YDERABAD ROAD, RAICHUR,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653503400,"product":"IBRUTINIB (TAX INVOICE NO:1905215446 DT","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY COMPANY ","customerCountry":"UNITED ARAB EMIRATES","quantity":"11.10","actualQuantity":"11.1","unit":"KGS","unitRateFc":"5940","totalValueFC":"65380.8","currency":"USD","unitRateINR":455225.22522522527,"date":"26-May-2022","totalValueINR":"5053000","totalValueInUsd":"65380.8","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"1661143","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653503400,"product":"IBRUTINIB (TAX INVOICE NO:1905225035 DT","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY COMPANY ","customerCountry":"UNITED ARAB EMIRATES","quantity":"11.10","actualQuantity":"11.1","unit":"KGS","unitRateFc":"5940","totalValueFC":"65406.6","currency":"USD","unitRateINR":455405.40540540544,"date":"26-May-2022","totalValueINR":"5055000","totalValueInUsd":"65406.6","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"1668221","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653676200,"product":"IBRUTINIB (TAX INVOICE NO:1905225053 DT","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEW YORK","customer":"TO THE ORDER OF","customerCountry":"UNITED STATES","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"8000","totalValueFC":"7828.1","currency":"USD","unitRateINR":605000,"date":"28-May-2022","totalValueINR":"605000","totalValueInUsd":"7828.1","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"1726134","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1658946600,"product":"FINE ORGANIC COMPOUND - IBRUTINIB\/1-((R)","address":"NO.49, F1 F2 CANARA BANK ROAD BOMMASANDRA INDL AREA PHASE I","city":"BENGALURU","supplier":"ANTHEM BIOSCIENCES","supplierCountry":"INDIA","foreign_port":"LJUBLJANA - BRNIK","customer":"PROJECT MANAGER","customerCountry":"SLOVENIA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10850","totalValueFC":"5382.5","currency":"USD","unitRateINR":856000,"date":"28-Jul-2022","totalValueINR":"428000","totalValueInUsd":"5382.5","indian_port":"BANGALORE AIR","hs_no":"29335400","bill_no":"3116123","productDescription":"API","marketType":"REGULATED MARKET","country":"SLOVENIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"NO.49, F1 F2 CANARA BANK ROAD BOMMASANDRA INDL AREA PHASE I, BENGALURU","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1660588200,"product":"IBRUTINIB","address":"ALEMBIC ROAD VADODARA Contact No: 919727727339","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"TO THE ORDER OF","customerCountry":"TAIWAN","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"25000","totalValueFC":"6133.2","currency":"USD","unitRateINR":1952000,"date":"16-Aug-2022","totalValueINR":"488000","totalValueInUsd":"6133.2","indian_port":"AHMEDABAD AIR","hs_no":"29335990","bill_no":"3522486","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"AHMEDABAD AIR","supplierAddress":"ALEMBIC ROAD VADODARA Contact No: 919727727339, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662143400,"product":"IBRUTINIB HYDROXY CAS 2031255-24-8","address":"302 VIJAYA TOWER, JAGRUT LANE VADAVALI SECTION","city":"AMBERNATH [E], DIST-THANE[INDIA]","supplier":"ANANT LABORATORIES","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"EUROFARMA LABORATORIOS S.A","customerCountry":"BRAZIL","quantity":"0.02","actualQuantity":"0.02","unit":"KGS","unitRateFc":"13500","totalValueFC":"262","currency":"USD","unitRateINR":1050000,"date":"03-Sep-2022","totalValueINR":"21000","totalValueInUsd":"262","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"3955169","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"302 VIJAYA TOWER, JAGRUT LANE VADAVALI SECTION, AMBERNATH [E], DIST-THANE[INDIA]","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662143400,"product":"IBRUTINIB HYDROXY CAS 2031255-24-8","address":"302 VIJAYA TOWER, JAGRUT LANE VADAVALI SECTION","city":"AMBERNATH [E], DIST-THANE[INDIA]","supplier":"ANANT LABORATORIES","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"EUROFARMA LABORATORIOS S.A","customerCountry":"BRAZIL","quantity":"0.04","actualQuantity":"0.04","unit":"KGS","unitRateFc":"10800","totalValueFC":"424.3","currency":"USD","unitRateINR":850000,"date":"03-Sep-2022","totalValueINR":"34000","totalValueInUsd":"424.3","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"3955169","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"302 VIJAYA TOWER, JAGRUT LANE VADAVALI SECTION, AMBERNATH [E], DIST-THANE[INDIA]","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662143400,"product":"IBRUTINIB HYDROXY CAS 2031255-24-8","address":"302 VIJAYA TOWER, JAGRUT LANE VADAVALI SECTION","city":"AMBERNATH [E], DIST-THANE[INDIA]","supplier":"ANANT LABORATORIES","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"EUROFARMA LABORATORIOS S.A","customerCountry":"BRAZIL","quantity":"0.07","actualQuantity":"0.07","unit":"KGS","unitRateFc":"9257.1","totalValueFC":"636.4","currency":"USD","unitRateINR":728571.42857142852,"date":"03-Sep-2022","totalValueINR":"51000","totalValueInUsd":"636.4","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"3955169","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"302 VIJAYA TOWER, JAGRUT LANE VADAVALI SECTION, AMBERNATH [E], DIST-THANE[INDIA]","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1662143400,"product":"IBRUTINIB N-OXIDE BATCH ANT-IBT-NO-110","address":"302 VIJAYA TOWER, JAGRUT LANE VADAVALI SECTION","city":"AMBERNATH [E], DIST-THANE[INDIA]","supplier":"ANANT LABORATORIES","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"EUROFARMA LABORATORIOS S.A","customerCountry":"BRAZIL","quantity":"0.04","actualQuantity":"0.04","unit":"KGS","unitRateFc":"6300","totalValueFC":"249.6","currency":"USD","unitRateINR":500000,"date":"03-Sep-2022","totalValueINR":"20000","totalValueInUsd":"249.6","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"3955169","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"302 VIJAYA TOWER, JAGRUT LANE VADAVALI SECTION, AMBERNATH [E], DIST-THANE[INDIA]","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1672165800,"product":"IBRUTINIB","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"SHANGHAI","customer":"KUNSHAN ROTAM REDDY","customerCountry":"CHINA","quantity":"61.00","actualQuantity":"61","unit":"KGS","unitRateFc":"8453.1","totalValueFC":"511844.7","currency":"USD","unitRateINR":691462.37704918033,"date":"28-Dec-2022","totalValueINR":"42179205","totalValueInUsd":"511844.7","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29420090","bill_no":"4000570","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1673375400,"product":"IBRUTINIB BATCH NO;ITBA22002","address":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE","city":"BANGALORE,KARNATAKA","supplier":"CDYMAX (INDIA) PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"M\/S,APOTEX INC,","customerCountry":"CANADA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"8333.3","totalValueFC":"2164.9","currency":"USD","unitRateINR":590000,"date":"11-Jan-2023","totalValueINR":"177000","totalValueInUsd":"2164.9","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"6883000","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675017000,"product":"IBRUTINIB DIMER (BATCH NO.BDP\/IBD\/2209-0","address":"UnitNOB4054thFloorSagarTechPlaza SakinakaJunctionAndheriEast Contact","city":"Mumbai","supplier":"BASIL DRUGS AND ","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"LABORATORIES ASPEN S.A.","customerCountry":"ARGENTINA","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"150000","totalValueFC":"1467.7","currency":"USD","unitRateINR":12000000,"date":"30-Jan-2023","totalValueINR":"120000","totalValueInUsd":"1467.7","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"7377406","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"UnitNOB4054thFloorSagarTechPlaza SakinakaJunctionAndheriEast Contact, Mumbai","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675103400,"product":"IBRUTINIB IHS(BATCH NO.VLS-IRB22004)(MFG","address":"UnitNOB4054thFloorSagarTechPlaza SakinakaJunctionAndheriEast Contact","city":"Mumbai","supplier":"BASIL DRUGS AND ","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"LABORATORIES ASPEN S.A.","customerCountry":"ARGENTINA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"5800","totalValueFC":"28327","currency":"USD","unitRateINR":463200,"date":"31-Jan-2023","totalValueINR":"2316000","totalValueInUsd":"28327","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"7394008","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"UnitNOB4054thFloorSagarTechPlaza SakinakaJunctionAndheriEast Contact, Mumbai","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675103400,"product":"IBRUTINIB IHS(BATCH NO.VLS-IRB22004)(MFG","address":"UnitNOB4054thFloorSagarTechPlaza SakinakaJunctionAndheriEast Contact","city":"Mumbai","supplier":"BASIL DRUGS AND ","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"LABORATORIES ASPEN S.A.","customerCountry":"ARGENTINA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"5800","totalValueFC":"28327","currency":"USD","unitRateINR":463200,"date":"31-Jan-2023","totalValueINR":"2316000","totalValueInUsd":"28327","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"7395885","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"UnitNOB4054thFloorSagarTechPlaza SakinakaJunctionAndheriEast Contact, Mumbai","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1675189800,"product":"IBRUTINIB IHS(BATCH NO.VLS-IRB22004)(MFG","address":"UnitNOB4054thFloorSagarTechPlaza SakinakaJunctionAndheriEast Contact","city":"Mumbai","supplier":"BASIL DRUGS AND ","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"LABORATORIOS ASPEN S.A.","customerCountry":"ARGENTINA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"5800","totalValueFC":"28042.1","currency":"USD","unitRateINR":463200,"date":"01-Feb-2023","totalValueINR":"2316000","totalValueInUsd":"28042.1","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"7454048","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"UnitNOB4054thFloorSagarTechPlaza SakinakaJunctionAndheriEast Contact, Mumbai","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1678645800,"product":"IBRUTINIB BATCH NO. 0121222 MFG.DT. AUG","address":"318 3RD FLOOR, U S COMPLEX MUTHURA ROAD, JASOLA","city":"NEW DELHI","supplier":"XENONE HEALTHCARE PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"ALMATY","customer":"PFK ELEAS LLP","customerCountry":"KAZAKHSTAN","quantity":"3.60","actualQuantity":"3.6","unit":"KGS","unitRateFc":"6192","totalValueFC":"21750.7","currency":"USD","unitRateINR":496944.44444444444,"date":"13-Mar-2023","totalValueINR":"1789000","totalValueInUsd":"21750.7","indian_port":"DELHI AIR","hs_no":"29335990","bill_no":"8424405","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"KAZAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"318 3RD FLOOR, U S COMPLEX MUTHURA ROAD, JASOLA, NEW DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1682015400,"product":"IBRUTINIB BATCH NO;ITBA22004","address":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE","city":"BANGALORE,KARNATAKA","supplier":"CDYMAX (INDIA) PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"M\/S,APOTEX INC,","customerCountry":"CANADA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"8333.3","totalValueFC":"2135.4","currency":"USD","unitRateINR":583333.33333333337,"date":"21-Apr-2023","totalValueINR":"175000","totalValueInUsd":"2135.4","indian_port":"BANGALORE AIR","hs_no":"29339990","bill_no":"9448927","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA, ,JIGANI 2ND PHASE, BANGALORE,KARNATAKA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1682965800,"product":"IBRUTINIB FORM A (MICRONISED ) IH","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"APOTEX INC","customerCountry":"CANADA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"6961.5","totalValueFC":"41320.3","currency":"USD","unitRateINR":566667.66666666663,"date":"02-May-2023","totalValueINR":"3400006","totalValueInUsd":"41320.3","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29420090","bill_no":"4000218","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Micronized","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1688063400,"product":"IBRUTINIB (OTHER) ((TAX INV MH116000012","address":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES","city":"MUMBAI,MAHARASHTRA","supplier":"BDR PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"HONG KONG","customer":"YULIANG LIMITED","customerCountry":"HONG KONG","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"9088.2","totalValueFC":"96415.6","currency":"EUR","unitRateINR":792500.02649999992,"date":"30-Jun-2023","totalValueINR":"7925000.265","totalValueInUsd":"96415.6","indian_port":"BOMBAY AIR","hs_no":"29420090","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"HONG KONG","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"407\/408 SHARDA CHAMBERS,NEW MARINE LINES, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689273000,"product":"IBRUTINIB IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"TO THE ORDER OF","customerCountry":"BRAZIL","quantity":"17.70","actualQuantity":"17.7","unit":"KGS","unitRateFc":"6000","totalValueFC":"105378.4","currency":"USD","unitRateINR":489322.05355932203,"date":"14-Jul-2023","totalValueINR":"8661000.348","totalValueInUsd":"105378.4","indian_port":"HYDERABAD AIR","hs_no":"29333200","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1689618600,"product":"IBRUTINIB BN.IBN\/121222 MD.AUG\/2022 ED.A","address":"318 3RD FLOOR, U S COMPLEX MUTHURA ROAD, JASOLA","city":"NEW DELHI","supplier":"XENONE HEALTHCARE PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"ALMATY","customer":"PFK ELEAS LLP","customerCountry":"KAZAKHSTAN","quantity":"10.24","actualQuantity":"10.24","unit":"KGS","unitRateFc":"11270","totalValueFC":"114430.6","currency":"USD","unitRateINR":918456.99257812498,"date":"18-Jul-2023","totalValueINR":"9404999.604","totalValueInUsd":"114430.6","indian_port":"DELHI AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"KAZAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"DELHI AIR","supplierAddress":"318 3RD FLOOR, U S COMPLEX MUTHURA ROAD, JASOLA, NEW DELHI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1696271400,"product":"IBRUTINIB (FORM-A)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NEW YORK - JOHN F. K","customer":"TO THE ORDER OF","customerCountry":"UNITED STATES","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"8000","totalValueFC":"15679.6","currency":"USD","unitRateINR":652500,"date":"03-Oct-2023","totalValueINR":"1305000","totalValueInUsd":"15679.6","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4368459","productDescription":"API","marketType":"REGULATED MARKET","country":"UNITED STATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1699209000,"product":"IBRUTINIB BATCH NO;ITBA22002P1","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX (INDIA) PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"M\/S,OZON LLC","customerCountry":"RUSSIA","quantity":"1.58","actualQuantity":"1.58","unit":"KGS","unitRateFc":"533000","totalValueFC":"9775.3","currency":"INR","unitRateINR":515189.87341772148,"date":"06-Nov-2023","totalValueINR":"814000","totalValueInUsd":"9775.3","indian_port":"Bangalore Air","hs_no":"29339990","bill_no":"5173307","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703183400,"product":"IBRUTINIB (FORM-A)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ULKAR HOLDING","customerCountry":"TURKEY","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"8000","totalValueFC":"3868.2","currency":"USD","unitRateINR":644000,"date":"22-Dec-2023","totalValueINR":"322000","totalValueInUsd":"3868.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6233029","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1703529000,"product":"IBRUTINIB BATCH NO;ITBA22004P1","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX (INDIA) PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"LABORATORIO ECZANE PHARMA","customerCountry":"ARGENTINA","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"4000","totalValueFC":"5574","currency":"USD","unitRateINR":309333.33333333331,"date":"26-Dec-2023","totalValueINR":"464000","totalValueInUsd":"5574","indian_port":"Bangalore Air","hs_no":"29339990","bill_no":"6301663","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704306600,"product":"IBRUTINIB (FORM-A)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"MONTREAL-DORAVAL APT","customer":"PHARMASCIENCE","customerCountry":"CANADA","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"6500","totalValueFC":"9508.5","currency":"USD","unitRateINR":526846.66666666663,"date":"04-Jan-2024","totalValueINR":"790270","totalValueInUsd":"9508.5","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6507525","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704911400,"product":"IBRUTINIB(FORM-A)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ALGIERS","customer":"SARL DEMOCEDES PHARMA ALGERIE","customerCountry":"ALGERIA","quantity":"13.00","actualQuantity":"13","unit":"KGS","unitRateFc":"5000","totalValueFC":"64041.5","currency":"USD","unitRateINR":409430.49230769236,"date":"11-Jan-2024","totalValueINR":"5322596.4","totalValueInUsd":"64041.5","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6666399","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ALGERIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1704997800,"product":"IBRUTINIB FORM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"LABORATORIOS VENT 3 S.R.L.","customerCountry":"ARGENTINA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"10000","totalValueFC":"4884.9","currency":"USD","unitRateINR":811991.26000000001,"date":"12-Jan-2024","totalValueINR":"405995.63","totalValueInUsd":"4884.9","indian_port":"Hyderabad Air","hs_no":"29333200","bill_no":"6706943","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1713983400,"product":"IBRUTINIB(FORM-M5)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"ULKAR HOLDING","customerCountry":"TURKEY","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"8000","totalValueFC":"3704.6","currency":"USD","unitRateINR":618714.76000000001,"date":"25-Apr-2024","totalValueINR":"309357.38","totalValueInUsd":"3704.6","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"9396578","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716229800,"product":"IBRUTINIB FPRM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF","customerCountry":"TURKEY","quantity":"40.00","actualQuantity":"40","unit":"KGS","unitRateFc":"4500","totalValueFC":"177998.1","currency":"USD","unitRateINR":370922.08175000001,"date":"21-May-2024","totalValueINR":"14836883.27","totalValueInUsd":"177998.1","indian_port":"Hyderabad Air","hs_no":"29333200","bill_no":"1054371","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717957800,"product":"IBRUTINIB FORM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TO THE ORDER OF","customerCountry":"TURKEY","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"4500","totalValueFC":"17711.8","currency":"USD","unitRateINR":369642.02000000002,"date":"10-Jun-2024","totalValueINR":"1478568.08","totalValueInUsd":"17711.8","indian_port":"Hyderabad Air","hs_no":"29333200","bill_no":"1565544","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1719513000,"product":"(REWARD ITEM)(PHARMACEUTICAL ALLOPATHICRAW MATERIAL OF PHARMACEUTICAL GRADE)IBRUTINIB(TAX INV.VLS\/EXP\/006\/2024-25)","address":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA","city":"N\/A","supplier":"VANNSH LIFE SCIENCES","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"M\/S PHARMASOL (PVT) LTD","customerCountry":"PAKISTAN","quantity":"0.58","actualQuantity":"576","unit":"GMS","unitRateFc":"11","totalValueFC":"6209","currency":"USD","unitRateINR":899.86675347222217,"date":"28-Jun-2024","totalValueINR":"518323.25","totalValueInUsd":"6209","indian_port":"Hyderabad Air","hs_no":"29332990","bill_no":"2025112","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"01-076\/3\/1A\/F1\/NR,1ST FLOOR, GANGA, N\/A","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721413800,"product":"IBRUTINIB FORM-A IH","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"TO THE ORDER OF","customerCountry":"RUSSIA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"6000","totalValueFC":"11781.9","currency":"USD","unitRateINR":492428.90500000003,"date":"20-Jul-2024","totalValueINR":"984857.81","totalValueInUsd":"11781.9","indian_port":"Hyderabad Air","hs_no":"29333200","bill_no":"2562940","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721586600,"product":"IBRUTINIB","address":"HETERO CORPORATE, NO. 7-2-A2,","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"HO CHI MINH C","customer":"TO THE ORDER OF","customerCountry":"VIETNAM","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"5000","totalValueFC":"19759.1","currency":"USD","unitRateINR":412921.25,"date":"22-Jul-2024","totalValueINR":"1651685","totalValueInUsd":"19759.1","indian_port":"Hyderabad Air","hs_no":"29333200","bill_no":"2615080","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"VIETNAM","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2,, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722364200,"product":"IBRUTINIB(FORM-A)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"EVA PHARMA FOR PHARMACEUTICALINDUST","customerCountry":"EGYPT","quantity":"9.70","actualQuantity":"9.7","unit":"KGS","unitRateFc":"3850","totalValueFC":"36876.4","currency":"USD","unitRateINR":317787.11340206186,"date":"31-Jul-2024","totalValueINR":"3082535","totalValueInUsd":"36876.4","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"2859274","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722969000,"product":"IBRUTINIB (B\/N;ITBB23002)","address":"N0 116\/117, KIADB INDUSTRIAL AREA,","city":"BANGALORE","supplier":"CDYMAX (INDIA) PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"LARNACA","customer":"REMEDICA LTD.","customerCountry":"CYPRUS","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"6800","totalValueFC":"39898.2","currency":"USD","unitRateINR":557766.76666666672,"date":"07-Aug-2024","totalValueINR":"3346600.6","totalValueInUsd":"39898.2","indian_port":"Bangalore Air","hs_no":"29339990","bill_no":"3022798","productDescription":"API","marketType":"REGULATED MARKET","country":"CYPRUS","selfForZScoreResived":"Pharma Grade","supplierPort":"Bangalore Air","supplierAddress":"N0 116\/117, KIADB INDUSTRIAL AREA,, BANGALORE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725561000,"product":"IBRUTINIB IH","address":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"GUARULHOS","customer":"LIBBS FARMACEUTICA","customerCountry":"BRAZIL","quantity":"8.10","actualQuantity":"8.1","unit":"KGS","unitRateFc":"6000","totalValueFC":"48222.3","currency":"USD","unitRateINR":498900,"date":"06-Sep-2024","totalValueINR":"4041090","totalValueInUsd":"48222.3","indian_port":"Hyderabad Air","hs_no":"29333200","bill_no":"3813713","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"BRAZIL","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"HETERO HOUSE,H.NO.8-3-166\/7\/1ERRAGADDA, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1727029800,"product":"IBRUTINIB (FORM-A)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"MONTREAL-DORAVAL APT","customer":"PHARMASCIENCE INC","customerCountry":"CANADA","quantity":"11.00","actualQuantity":"11","unit":"KGS","unitRateFc":"6500","totalValueFC":"70574.2","currency":"USD","unitRateINR":537654.99818181817,"date":"23-Sep-2024","totalValueINR":"5914204.98","totalValueInUsd":"70574.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4271901","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657218600,"product":"(N.C.V) IBRUTINIB (API) 1-(3R)-3-[4-AMINO-3-(4-PHENOXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]-1-PIPERIDINYL-2-PROPEN-1","address":"L.B.S. MARG,,MULUND-WEST","city":"MUMBAI,MAHARASHTRA","supplier":"CHANGZHOU SYNTHEALL PHARMACEUTICAL CO., LTD.","supplierCountry":"CHINA","foreign_port":"NA","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.63","actualQuantity":"0.626","unit":"KGS","unitRateFc":"2685.5","totalValueFC":"2140.5","currency":"USD","unitRateINR":"271892.8","date":"08-Jul-2022","totalValueINR":"170204.89","totalValueInUsd":"2140.5","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"9468074","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"NA","supplierAddress":"","customerAddress":"L.B.S. MARG,,MULUND-WEST"},{"dataSource":"API Import","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1699554600,"product":"CHEMICAL : IBRUTINIB","address":"10\/13, NR. M.N. DESAI PETROL PUMP","city":"AHMEDABAD, GUJARAT","supplier":"SHANGHAI ACEBRIGHT PHARMACEUTICALS ","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"SAKAR HEALTHCARE LIMITED","customerCountry":"INDIA","quantity":"0.90","actualQuantity":"0.9","unit":"KGS","unitRateFc":"9000","totalValueFC":"8185.5","currency":"USD","unitRateINR":"757350","date":"10-Nov-2023","totalValueINR":"681615","totalValueInUsd":"8185.5","indian_port":"Ahmedabad Air","hs_no":"29339990","bill_no":"8712930","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"BUILDING NO.5, 1999 ZHANGHENG ROAD,ZHANGJIANG HI-TECH PARK, SHANGHAI201203, CHINA CHINA","customerAddress":"10\/13, NR. M.N. DESAI PETROL PUMP"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705861800,"product":"IBRUTINIB -(FOC)-FOR TESTING PURPOSE ONLY","address":"M-34, SAKET,","city":"NEW DELHI,DELHI","supplier":"CHEMICAL INDUSTRIES ASSOCIATION","supplierCountry":"ISRAEL","foreign_port":"TEL AVIV YAFO","customer":"TEVA API","customerCountry":"INDIA","quantity":"0.30","actualQuantity":"300","unit":"GMS","unitRateFc":"5","totalValueFC":"1517.8","currency":"USD","unitRateINR":"420.5","date":"22-Jan-2024","totalValueINR":"126150","totalValueInUsd":"1517.8","indian_port":"Delhi Air","hs_no":"29339990","bill_no":"9780749","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ISRAEL","selfForZScoreResived":"Pharma Grade","supplierPort":"TEL AVIV YAFO","supplierAddress":"TEVA API DIVISION NEOT-HOVAV ECOINDUSTRIAL PARK P.O. BOX 2049 BEERSHEVA 8412316 IL","customerAddress":"M-34, SAKET,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722796200,"product":"IBRUTINIB","address":"SANDOZ HOUSE","city":"MUMBAI ,MAHARASHTRA","supplier":"SANDOZ B2B","supplierCountry":"AUSTRALIA","foreign_port":"MUNICH","customer":"SANDOZ B2B","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"9.4","unit":"GMS","unitRateFc":"100","totalValueFC":"1033.8","currency":"EUR","unitRateINR":"9225","date":"05-Aug-2024","totalValueINR":"86715","totalValueInUsd":"1033.8","indian_port":"Hyderabad Air","hs_no":"29349990","bill_no":"4896242","productDescription":"API","marketType":"REGULATED MARKET","country":"AUSTRALIA","selfForZScoreResived":"Pharma Grade","supplierPort":"MUNICH","supplierAddress":"BIOCHEMIESTR .10 B122A-6250 KUNDI\/TIROLAUSTRIA AT","customerAddress":"SANDOZ HOUSE"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1722882600,"product":"IBRUTINIB API","address":"F 2, NO.18-17, CITY HOME RESIDENCY,","city":"HYDERABAD, AP.","supplier":"GYMA LABORATORIES OF AMERICA, INC.","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"SP ACCURE LABS PVT. LTD","customerCountry":"INDIA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"15000","totalValueFC":"91258.2","currency":"USD","unitRateINR":"1275768","date":"06-Aug-2024","totalValueINR":"7654608","totalValueInUsd":"91258.2","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"4913629","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"210 CROSSWAYS PARK DRIVE, SUITE 100WOODBURY, NY 11797SDNF US","customerAddress":"F 2, NO.18-17, CITY HOME RESIDENCY,"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1725906600,"product":"(N.C.V) JNJ-54179060-AAA IBRUTINIB API 1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1-YL]-1-PIPERI","address":"30 FORJETT STREET","city":"MUMBAI, MAHARASHTRA.","supplier":"CHANGZHOU SYN THE ALL PHARMACEUTICAL CO LTD","supplierCountry":"CHINA","foreign_port":"SHANGHAI - PU DONG","customer":"JOHNSON & JOHNSON","customerCountry":"INDIA","quantity":"0.10","actualQuantity":"96","unit":"GMS","unitRateFc":"2.7","totalValueFC":"261.1","currency":"USD","unitRateINR":"228","date":"10-Sep-2024","totalValueINR":"21883.82","totalValueInUsd":"261.1","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"5523025","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI - PU DONG","supplierAddress":"589 NORTH YULONG ROAD , XINBEI DIST RICT CHANGZHOU 213127, JIANGSU Chan gzhou, , China China China","customerAddress":"30 FORJETT STREET"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1726252200,"product":"IBRUTINIB","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR","city":"AHMEDABAD\/GUJRAT","supplier":"ESTEVE QUIMICA","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"ZYDUS LIFESCIENCES LIMITED","customerCountry":"INDIA","quantity":"16.35","actualQuantity":"16.347","unit":"KGS","unitRateFc":"8886.7","totalValueFC":"147175.7","currency":"USD","unitRateINR":"754481.2","date":"14-Sep-2024","totalValueINR":"12333503.66","totalValueInUsd":"147175.7","indian_port":"Ahmedabad-ZIPL-SEZ","hs_no":"29335990","bill_no":"5616585","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"TORRE ESTEVE, PG DE LA ZONA FRANCA 109 4 PLANTA BARCELONA SDNF Spain","customerAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR"}]
    16-Mar-2021
    23-Sep-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Europe

    read-more
    read-more

    01

    BLUEPHARMA - INDUSTRIA FARMACEUTICA, S.A

    Portugal
    Compamed
    Not Confirmed
    arrow

    BLUEPHARMA - INDUSTRIA FARMACEUTICA, S.A

    Portugal
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Portugal
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Portugal

    IBRUTINIB

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength : 140MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Portugal

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    BLUEPHARMA - INDUSTRIA FARMACEUTICA, S.A

    Portugal
    Compamed
    Not Confirmed
    arrow

    BLUEPHARMA - INDUSTRIA FARMACEUTICA, S.A

    Portugal
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Portugal
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Portugal

    IBRUTINIB

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength : 280MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Portugal

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    BLUEPHARMA - INDUSTRIA FARMACEUTICA, S.A

    Portugal
    Compamed
    Not Confirmed
    arrow

    BLUEPHARMA - INDUSTRIA FARMACEUTICA, S.A

    Portugal
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Portugal
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Portugal

    IBRUTINIB

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength : 420MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Portugal

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    BLUEPHARMA - INDUSTRIA FARMACEUTICA, S.A

    Portugal
    Compamed
    Not Confirmed
    arrow

    BLUEPHARMA - INDUSTRIA FARMACEUTICA, S.A

    Portugal
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Portugal
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Portugal

    IBRUTINIB

    Brand Name :

    Dosage Form : Tablet

    Dosage Strength : 560MG

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Portugal

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    JANSSEN CILAG INTERNAT.N.V.

    Italy
    Compamed
    Not Confirmed
    arrow

    JANSSEN CILAG INTERNAT.N.V.

    Italy
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    IBRUTINIB

    Brand Name : Imbruvica

    Dosage Form : Ibrutinib 140Mg 90 Combined Oral Use

    Dosage Strength : 90 cps 140 mg bottle

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    JANSSEN CILAG INTERNAT.N.V.

    Italy
    Compamed
    Not Confirmed
    arrow

    JANSSEN CILAG INTERNAT.N.V.

    Italy
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Italy

    IBRUTINIB

    Brand Name : Imbruvica

    Dosage Form : Ibrutinib 140Mg 120 Unita' Oral Use

    Dosage Strength : 120 cps 140 mg bottle

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Italy

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Janssen-Cilag International N.V.

    Italy
    Compamed
    Not Confirmed
    arrow

    Janssen-Cilag International N.V.

    Italy
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    IBRUTINIB

    Brand Name : Imbruvica

    Dosage Form : Capsule, hard

    Dosage Strength : 140 mg

    Packaging : Box

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Janssen-Cilag International N.V.

    Italy
    Compamed
    Not Confirmed
    arrow

    Janssen-Cilag International N.V.

    Italy
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Norway

    IBRUTINIB

    Brand Name : Imbruvica

    Dosage Form : Capsule, hard

    Dosage Strength : 140 mg

    Packaging : Box

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Norway

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Janssen-Cilag AG

    Italy
    Compamed
    Not Confirmed
    arrow

    Janssen-Cilag AG

    Italy
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Ibrutinib

    Brand Name : Imbruvica

    Dosage Form : Film-Coated Tablets

    Dosage Strength : 140mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Janssen-Cilag AG

    Italy
    Compamed
    Not Confirmed
    arrow

    Janssen-Cilag AG

    Italy
    arrow
    Compamed
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Italy
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Regulatory Info :

    Registration Country : Switzerland

    Ibrutinib

    Brand Name : Imbruvica

    Dosage Form : Film-Coated Tablets

    Dosage Strength : 280mg

    Packaging :

    Approval Date :

    Application Number :

    Regulatory Info :

    Registration Country : Switzerland

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    STOCK RECAP #PipelineProspector

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    US Exclusivities

    read-more
    read-more

    PHARMACYCLICS LLC

    Contact Supplier
      • fda
      • EDQM
      • WHO-GMP
      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
      Contact Supplier Contact Supplier
      Flag U.S.A
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      IBRUTINIB

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      ODE-152
      2024-08-02
      205552
      1
      Abbvie company banner

      01

      PHARMACYCLICS LLC

      U.S.A
      arrow
      euroPLX 86 Munich
      Not Confirmed

      IBRUTINIB

      Exclusivity Code : ODE-152

      Exclusivity Expiration Date : 2024-08-02

      Application Number : 205552

      Product Number : 1

      Exclusivity Details :

      Abbvie company banner

      Portfolio PDF

      Product Web Link

      Virtual Booth

      Digital Content

      Website

      Corporate PDF

      PHARMACYCLICS LLC

      Contact Supplier
        • fda
        • EDQM
        • WHO-GMP
        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
        Contact Supplier Contact Supplier
        Flag U.S.A
        Virtual Booth Virtual Booth
        Digital Content Digital Content

        IBRUTINIB

        Portfolio PDF

        Product Web Link

        Virtual Booth

        Digital Content

        Website

        Corporate PDF

        M-14
        2025-08-24
        205552
        1
        Abbvie company banner

        02

        PHARMACYCLICS LLC

        U.S.A
        arrow
        euroPLX 86 Munich
        Not Confirmed

        IBRUTINIB

        Exclusivity Code : M-14

        Exclusivity Expiration Date : 2025-08-24

        Application Number : 205552

        Product Number : 1

        Exclusivity Details :

        Abbvie company banner

        Portfolio PDF

        Product Web Link

        Virtual Booth

        Digital Content

        Website

        Corporate PDF

        PHARMACYCLICS LLC

        Contact Supplier
          • fda
          • EDQM
          • WHO-GMP
          Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
          Contact Supplier Contact Supplier
          Flag U.S.A
          Virtual Booth Virtual Booth
          Digital Content Digital Content

          IBRUTINIB

          Portfolio PDF

          Product Web Link

          Virtual Booth

          Digital Content

          Website

          Corporate PDF

          ODE-405
          2029-08-24
          205552
          1
          Abbvie company banner

          03

          PHARMACYCLICS LLC

          U.S.A
          arrow
          euroPLX 86 Munich
          Not Confirmed

          IBRUTINIB

          Exclusivity Code : ODE-405

          Exclusivity Expiration Date : 2029-08-24

          Application Number : 205552

          Product Number : 1

          Exclusivity Details :

          Abbvie company banner

          Portfolio PDF

          Product Web Link

          Virtual Booth

          Digital Content

          Website

          Corporate PDF

          PHARMACYCLICS LLC

          Contact Supplier
            • fda
            • EDQM
            • WHO-GMP
            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
            Contact Supplier Contact Supplier
            Flag U.S.A
            Virtual Booth Virtual Booth
            Digital Content Digital Content

            IBRUTINIB

            Portfolio PDF

            Product Web Link

            Virtual Booth

            Digital Content

            Website

            Corporate PDF

            NPP
            2025-08-24
            205552
            1
            Abbvie company banner

            04

            PHARMACYCLICS LLC

            U.S.A
            arrow
            euroPLX 86 Munich
            Not Confirmed

            IBRUTINIB

            Exclusivity Code : NPP

            Exclusivity Expiration Date : 2025-08-24

            Application Number : 205552

            Product Number : 1

            Exclusivity Details :

            Abbvie company banner

            Portfolio PDF

            Product Web Link

            Virtual Booth

            Digital Content

            Website

            Corporate PDF

            PHARMACYCLICS LLC

            Contact Supplier
              • fda
              • EDQM
              • WHO-GMP
              Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IBRUTINIB

              Portfolio PDF

              Product Web Link

              Virtual Booth

              Digital Content

              Website

              Corporate PDF

              M-14
              2025-08-24
              205552
              2
              Abbvie company banner

              05

              PHARMACYCLICS LLC

              U.S.A
              arrow
              euroPLX 86 Munich
              Not Confirmed

              IBRUTINIB

              Exclusivity Code : M-14

              Exclusivity Expiration Date : 2025-08-24

              Application Number : 205552

              Product Number : 2

              Exclusivity Details :

              Abbvie company banner

              Portfolio PDF

              Product Web Link

              Virtual Booth

              Digital Content

              Website

              Corporate PDF

              PHARMACYCLICS LLC

              Contact Supplier
                • fda
                • EDQM
                • WHO-GMP
                Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
                Contact Supplier Contact Supplier
                Flag U.S.A
                Virtual Booth Virtual Booth
                Digital Content Digital Content

                IBRUTINIB

                Portfolio PDF

                Product Web Link

                Virtual Booth

                Digital Content

                Website

                Corporate PDF

                ODE-405
                2029-08-24
                205552
                2
                Abbvie company banner

                06

                PHARMACYCLICS LLC

                U.S.A
                arrow
                euroPLX 86 Munich
                Not Confirmed

                IBRUTINIB

                Exclusivity Code : ODE-405

                Exclusivity Expiration Date : 2029-08-24

                Application Number : 205552

                Product Number : 2

                Exclusivity Details :

                Abbvie company banner

                Portfolio PDF

                Product Web Link

                Virtual Booth

                Digital Content

                Website

                Corporate PDF

                PHARMACYCLICS LLC

                Contact Supplier
                  • fda
                  • EDQM
                  • WHO-GMP
                  Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
                  Contact Supplier Contact Supplier
                  Flag U.S.A
                  Virtual Booth Virtual Booth
                  Digital Content Digital Content

                  IBRUTINIB

                  Portfolio PDF

                  Product Web Link

                  Virtual Booth

                  Digital Content

                  Website

                  Corporate PDF

                  ODE*
                  2024-08-02
                  205552
                  2
                  Abbvie company banner

                  07

                  PHARMACYCLICS LLC

                  U.S.A
                  arrow
                  euroPLX 86 Munich
                  Not Confirmed

                  IBRUTINIB

                  Exclusivity Code : ODE*

                  Exclusivity Expiration Date : 2024-08-02

                  Application Number : 205552

                  Product Number : 2

                  Exclusivity Details :

                  Abbvie company banner

                  Portfolio PDF

                  Product Web Link

                  Virtual Booth

                  Digital Content

                  Website

                  Corporate PDF

                  PHARMACYCLICS LLC

                  Contact Supplier
                    • fda
                    • EDQM
                    • WHO-GMP
                    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
                    Contact Supplier Contact Supplier
                    Flag U.S.A
                    Virtual Booth Virtual Booth
                    Digital Content Digital Content

                    IBRUTINIB

                    Portfolio PDF

                    Product Web Link

                    Virtual Booth

                    Digital Content

                    Website

                    Corporate PDF

                    NPP
                    2025-08-24
                    205552
                    2
                    Abbvie company banner

                    08

                    PHARMACYCLICS LLC

                    U.S.A
                    arrow
                    euroPLX 86 Munich
                    Not Confirmed

                    IBRUTINIB

                    Exclusivity Code : NPP

                    Exclusivity Expiration Date : 2025-08-24

                    Application Number : 205552

                    Product Number : 2

                    Exclusivity Details :

                    Abbvie company banner

                    Portfolio PDF

                    Product Web Link

                    Virtual Booth

                    Digital Content

                    Website

                    Corporate PDF

                    PHARMACYCLICS LLC

                    Contact Supplier
                      • fda
                      • EDQM
                      • WHO-GMP
                      Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
                      Contact Supplier Contact Supplier
                      Flag U.S.A
                      Virtual Booth Virtual Booth
                      Digital Content Digital Content

                      IBRUTINIB

                      Portfolio PDF

                      Product Web Link

                      Virtual Booth

                      Digital Content

                      Website

                      Corporate PDF

                      M-14
                      2025-08-24
                      210563
                      4
                      Abbvie company banner

                      09

                      PHARMACYCLICS LLC

                      U.S.A
                      arrow
                      euroPLX 86 Munich
                      Not Confirmed

                      IBRUTINIB

                      Exclusivity Code : M-14

                      Exclusivity Expiration Date : 2025-08-24

                      Application Number : 210563

                      Product Number : 4

                      Exclusivity Details :

                      Abbvie company banner

                      Portfolio PDF

                      Product Web Link

                      Virtual Booth

                      Digital Content

                      Website

                      Corporate PDF

                      PHARMACYCLICS LLC

                      Contact Supplier
                        • fda
                        • EDQM
                        • WHO-GMP
                        Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
                        Contact Supplier Contact Supplier
                        Flag U.S.A
                        Virtual Booth Virtual Booth
                        Digital Content Digital Content

                        IBRUTINIB

                        Portfolio PDF

                        Product Web Link

                        Virtual Booth

                        Digital Content

                        Website

                        Corporate PDF

                        ODE-405
                        2029-08-24
                        210563
                        4
                        Abbvie company banner

                        10

                        PHARMACYCLICS LLC

                        U.S.A
                        arrow
                        euroPLX 86 Munich
                        Not Confirmed

                        IBRUTINIB

                        Exclusivity Code : ODE-405

                        Exclusivity Expiration Date : 2029-08-24

                        Application Number : 210563

                        Product Number : 4

                        Exclusivity Details :

                        Abbvie company banner

                        Portfolio PDF

                        Product Web Link

                        Virtual Booth

                        Digital Content

                        Website

                        Corporate PDF

                        Only 10 entries up to this point, click to access all click full view read-more
                        click full view
                        Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

                        REF. STANDARDS & IMPURITIES

                        Upload your portfolio for free, ask us

                        ABOUT THIS PAGE

                        Ask Us for Pharmaceutical Supplier and Partner
                        Ask Us, Find A Supplier / Partner
                        No Commissions, No Strings Attached, Get Connected for FREE

                        What are you looking for?

                        How can we help you?

                        The request can't be empty

                        Please read our Privacy Policy carefully

                        You must agree to the privacy policy

                        The name can't be empty
                        The company can't be empty.
                        The email can't be empty Please enter a valid email.
                        The mobile can't be empty

                        Market Place

                        Market Place

                        PharmaCompass

                        Home

                        Market Place

                        Menu

                        Post Enquiry

                        Post Enquiry

                        Market Place

                        Market Place

                        Search